All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681494/
https://www.ncbi.nlm.nih.gov/pubmed/23238683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681494/
https://www.ncbi.nlm.nih.gov/pubmed/23238683

Ejemplares similares